Abstract
Cancer is a leading cause of death worldwide. The expression of COX-2 and prostaglandins has not only been associated with various types of cancer but is also directly proportional to their aggressiveness including metastasis. Thus, inhibition of COX-2 activity has been one of the preferred targets for cancer reduction. Broad spectrum inhibition of all forms of COX (using NSAIDs) is associated with various side effects ranging from gastric ulceration to renal problems. Even specific COX-2 inhibitors (COXIBs) are associated with side effects like myocardial infarction. Alternative strategies including siRNA technology are also not very victorious due to their off-target associated problems. Thus, there is an urgent need for the development of strategies where COX-2 activity may be reduced without inducing any side effects. One of the approaches for designing novel inhibitors may be to target various molecules downstream of COX-2. In this review, we have tried to cover the basic biology of COX-2 and its association with different types of cancer. Various generations of COX-2 inhibitors have been covered with their merits and demerits. Possible exploitation of novel targets like EP receptors, mPGES and various other downstream molecules which can be utilized for a better COX-2 signaling inhibition and thus efficient cancer reduction with minimal side effects has been discussed.
Keywords: Cancer, COXIBs, cyclooxygenase-2, NSAIDs, mPGES-1, EP receptors.
Current Drug Targets
Title:COX-2 Signaling and Cancer: New Players in Old Arena
Volume: 15 Issue: 3
Author(s): Shashank Misra and Kulbhushan Sharma
Affiliation:
Keywords: Cancer, COXIBs, cyclooxygenase-2, NSAIDs, mPGES-1, EP receptors.
Abstract: Cancer is a leading cause of death worldwide. The expression of COX-2 and prostaglandins has not only been associated with various types of cancer but is also directly proportional to their aggressiveness including metastasis. Thus, inhibition of COX-2 activity has been one of the preferred targets for cancer reduction. Broad spectrum inhibition of all forms of COX (using NSAIDs) is associated with various side effects ranging from gastric ulceration to renal problems. Even specific COX-2 inhibitors (COXIBs) are associated with side effects like myocardial infarction. Alternative strategies including siRNA technology are also not very victorious due to their off-target associated problems. Thus, there is an urgent need for the development of strategies where COX-2 activity may be reduced without inducing any side effects. One of the approaches for designing novel inhibitors may be to target various molecules downstream of COX-2. In this review, we have tried to cover the basic biology of COX-2 and its association with different types of cancer. Various generations of COX-2 inhibitors have been covered with their merits and demerits. Possible exploitation of novel targets like EP receptors, mPGES and various other downstream molecules which can be utilized for a better COX-2 signaling inhibition and thus efficient cancer reduction with minimal side effects has been discussed.
Export Options
About this article
Cite this article as:
Misra Shashank and Sharma Kulbhushan, COX-2 Signaling and Cancer: New Players in Old Arena, Current Drug Targets 2014; 15 (3) . https://dx.doi.org/10.2174/1389450115666140127102915
DOI https://dx.doi.org/10.2174/1389450115666140127102915 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Antibiotic Effects of Vitamin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Peptides Neutralizing Lipopolysaccharide - Structure and Function
Mini-Reviews in Medicinal Chemistry The Effects of Trifluoromethylated Derivatives on Prostaglandin E<sub>2</sub> and Thromboxane A<sub>2</sub> Production in Human Leukemic U937 Macrophages
Medicinal Chemistry Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Structural Basis and Therapeutic Implication of the Interaction of CCN Proteins with Glycoconjugates
Current Pharmaceutical Design Prospective Trial of an Herbal Formula BYSH and Saw Palmetto in Patients with Hormonal Refractory Prostate Cancer: A Pilot Study
Recent Patents on Inflammation & Allergy Drug Discovery Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases
Current Drug Metabolism Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation
Current Alzheimer Research Apoptosis: Its Functions and Control in the Ocular Lens
Current Molecular Medicine Mechanisms and Therapeutic Implications of Asthma Circadian Rhythm
Current Respiratory Medicine Reviews Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association
Current Pharmaceutical Design Xanthohumol, a Prenylated Chalcone Derived from Hops, Suppresses Cancer Cell Invasion through Inhibiting the Expression of CXCR4 Chemokine Receptor
Current Molecular Medicine Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics
Current Medicinal Chemistry Structural Disorder within the Measles Virus Nucleoprotein and Phosphoprotein
Protein & Peptide Letters Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Mentha L. Species (Lamiaceae) as Promising Sources of Bioactive Secondary Metabolites
Current Pharmaceutical Design The Role of Chemokines in the Pathogenesis of Rheumatoid Arthritis
Current Rheumatology Reviews The Arrestin Fold: Variations on a Theme
Current Genomics Cytokines in Haemopoietic Progenitor Mobilisation for Peripheral Blood Stem Cell Transplantation
Current Pharmaceutical Design